Categoria Scientific Articles
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Survival with Cemiplimab in Recurrent Cervical Cancer
Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomized, double-blind, placebo-controlled, phase 3 trial
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Genomic Profiling of Lung Adenocarcinoma in Never-Smokers
Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer. The Phase 2 Single-Arm Clinical CAVE Trial
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial
Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-Positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)
Patient-reported outcomes predict progression-free survival of patients with advanced breast cancer treated with abemaciclib
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Effects of mindfulness-based interventions on fatigue in cancer survivors: A systematic review and meta-analysis of randomized controlled trials
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Breast Cancer Risk Genes – Association Analysis in More than 113,000 Women
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Patient associations and clinical oncology research: how much does a patient’s voice really matter?
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
HPV Vaccination and the Risk of Invasive Cervical Cancer
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Capmatinib In MET Exon 14–Mutated Or MET-Amplified Non–Small-Cell Lung Cancer
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations
Prognostic Value of HER2 Status on Circulating Tumor Cells in Advanced-Stage Breast Cancer Patients With HER2-negative Tumors
Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Cancer risk following lymphoid malignancies among HIV-infected people
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
COVID-19 Emergency and the Need to Speed Up the Adoption of Electronic Patient-Reported Outcomes in Cancer Clinical Practice
The Use of Not-Negative Conclusions to Describe Results of Formally Negative Trials Presented at Oncology Meetings
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial
Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
Effects of Intermittent Fasting on Health, Aging, and Disease
Lorlatinib in Advanced ROS1-positive Non-Small-Cell Lung Cancer: A Multicentre, Open-Label, Single-Arm, Phase 1-2 Trial
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Hype or hope? The strange case of platinum salts’ renaissance in breast cancer
Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types
Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum
The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma: A Reclassification Study by the Spanish Group For Ovarian Cancer Research (GEICO)
Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
Association of Early Palliative Care Use With Survival and Place of Death Among Patients With Advanced Lung Cancer Receiving Care in the Veterans Health Administration
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
